Literature DB >> 36175651

New PEARLS of adjuvant wisdom.

David Killock1.   

Abstract

Entities:  

Year:  2022        PMID： 36175651     DOI： 10.1038/s41571-022-00690-6

Source DB:  PubMed          Journal:  Nat Rev Clin Oncol        ISSN： 1759-4774            Impact factor:   65.011


× No keyword cloud information.
  1 in total

1.  Pembrolizumab versus placebo as adjuvant therapy for completely resected stage IB-IIIA non-small-cell lung cancer (PEARLS/KEYNOTE-091): an interim analysis of a randomised, triple-blind, phase 3 trial.

Authors:  Mary O'Brien; Luis Paz-Ares; Sandrine Marreaud; Urania Dafni; Kersti Oselin; Libor Havel; Emilio Esteban; Dolores Isla; Alex Martinez-Marti; Martin Faehling; Masahiro Tsuboi; Jong-Seok Lee; Kazuhiko Nakagawa; Jing Yang; Ayman Samkari; Steven M Keller; Murielle Mauer; Nitish Jha; Rolf Stahel; Benjamin Besse; Solange Peters
Journal:  Lancet Oncol       Date:  2022-09-12       Impact factor: 54.433
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.